Economic footprint of the pharma sector in Bulgaria
The total contribution that the pharmaceutical industry has provided for the Bulgarian economy in 2021 is estimated at around 2.8 billion Bulgarian lev ($1.57 billion) or 2.2% of the country's gross domestic product (GDP), which is in line with the average level for Europe.
These and other data were presented for the first time by Luka Chichov, executive director of IQVIA for Central and Eastern Europe, in a report delivered during an expert meeting of the economic and strategic contribution of the pharmaceutical sector in Bulgaria, which was organized by the country’s trade organizations representing pharma and generics companies as well as wholesalers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze